Renal and related cancers
Renal and related cancers is a research topic within Molecular Biology. Science Explorer counts 38k research works in it since 1950. 18.7% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the molecular mechanisms underlying kidney development, including the use of kidney organoids derived from pluripotent stem cells to model nephrogenesis and injury. It also delves into the role of specific genes such as WT1, the signaling pathways like GDNF/Ret, and the cellular processes involved in branching morphogenesis. Additionally, it covers topics related to congenital anomalies, podocyte development, and Wilms tumor, providing a comprehensive understanding of kidney development and disease.
- Kidney Organoids
- Nephrogenesis
- WT1 Gene
- Renal Progenitors
- Branching Morphogenesis
- GDNF/Ret Signaling
- Pluripotent Stem Cells
- Congenital Anomalies
- Podocyte Development
- Wilms Tumor
- Research works
- 38k fractional, since 1950
- In the world top 10%
- 7k per year above
- Top-10% rate
- 18.7% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +11% the tick is no change
Which countries lead Renal and related cancers research?
By volume, the United States and China publish the most (1.4k and 1.1k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.4k works
- 2 China 1.1k works
- 3 Japan 315 works
- 4 India 264 works
- 5 Germany 225 works
- 6 United Kingdom 205 works
- 7 Italy 203 works
- 8 France 150 works
- 9 Canada 118 works
- 10 Spain 109 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Renal and related cancers research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Renal and related cancers research, followed by Harvard University and All India Institute of Medical Sciences.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 22 works
- 2 Harvard UniversityUnited States 21 works
- 3 All India Institute of Medical SciencesIndia 20 works
- 4 The University of Texas Southwestern Medical CenterUnited States 19 works
- 5 University of Southern CaliforniaUnited States 19 works
- 6 University of PennsylvaniaUnited States 18 works
- 7 University of MichiganUnited States 18 works
- 8 Washington University in St. LouisUnited States 17 works
- 9 Sun Yat-sen UniversityChina 17 works
- 10 Shanghai Jiao Tong UniversityChina 17 works
Who are the leading researchers in Renal and related cancers?
The most-cited researchers publishing on Renal and related cancers include Giuseppe Remuzzi, Norberto Perico and David F. McDermott.
- 1 Giuseppe Remuzzi Italy 8.1k citations
- 2 Norberto Perico Italy 6.1k citations
- 3 David F. McDermott United States 3.1k citations
- 4 Michael B. Atkins United States 3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Renal and related cancers research done?
The largest centres of Renal and related cancers research in 2022–2025 are Beijing (China), Shanghai (China), Tokyo (Japan) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Cincinnati, Bethesda and Dallas.
Largest cities, 2022–2025
Where it is the local speciality
- CincinnatiUS · 22.5 works5.5×
- BethesdaUS · 33.3 works5.2×
- DallasUS · 21.1 works5.1×
- NashvilleUS · 24.1 works4.9×
Location quotient: how much more of its research is in Renal and related cancers than the world average.
Where is the best place to study Renal and related cancers?
Among universities, judged by research, Washington University in St. Louis, Harvard University and Medical University of Vienna score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Washington University in St. LouisUnited States | 56.0 | 34.7% | 4.7× | 17 | -9.4% |
| 2 | Harvard UniversityUnited States | 54.9 | 28.9% | 3.2× | 21 | -15.1% |
| 3 | Medical University of ViennaAustria | 50.5 | 40.7% | 5.5× | 9 | -56.3% |
| 4 | University of Southern CaliforniaUnited States | 49.8 | 19.7% | 4.9× | 19 | +34.1% |
| 5 | Yale UniversityUnited States | 48.5 | 25.5% | 3.2× | 16 | +48.6% |
| 6 | Chinese University of Hong KongHong Kong | 45.4 | 40.0% | 2.3× | 8 | -21.5% |
| 7 | Icahn School of Medicine at Mount SinaiUnited States | 45.1 | 16.1% | 5.8× | 15 | +34.3% |
| 8 | Nanjing Medical UniversityChina | 44.8 | 17.6% | 5.9× | 16 | +22.0% |
| 9 | Guangzhou Medical UniversityChina | 43.7 | 8.2% | 7.7× | 11 | +142.2% |
| 10 | University of PennsylvaniaUnited States | 42.5 | 18.5% | 3.8× | 18 | -12.1% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Renal and related cancers research growing?
Output in 2018–2022 was 11% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are Renal and related cancers.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.